Research use only. Not for human or animal consumption.La Jolla, CaliforniaLot lookupContact
MAROGENBIO

Format guide

Tirzepatide (GP-2) and Retatrutide (GP-3) pens

Two 20 mg prefilled research pens, two large lipidated peptides about 82 Da apart, and two product names that are not chemical names. What is in each pen, how to identify it, and what documentation to require.

Catalog formats covered
2
Papers cited
4
Last reviewed
2026-11-12
Classification
Research use only
Buying this material?
Apply for wholesale pricing
01

What is in each pen

Published chemistry for the fill, not a measurement from any lot.

The pen listed as GLP-2 contains tirzepatide, development code LY3298176: a synthetic 39-residue lipidated peptide amide based on the human GIP sequence, with Aib at positions 2 and 13, a C20 fatty diacid at Lys20 attached through a gamma-glutamate and two glycol units, and a C-terminal serinamide. Formula C225H348N48O68, 4813.5 g/mol, figures that agree across PubChem and the FDA registry.

The pen listed as GLP-3 contains retatrutide, development code LY3437943: a synthetic lipidated peptide on a glucagon-family backbone, recorded in the FDA registry with a 39-residue backbone under UNII NOP2Y096GV. Its published formula C221H342N46O68 and weight of 4731.3 g/mol match PubChem and vendor datasheets but are unconfirmed in CAS Common Chemistry, so Marogen marks the entry as awaiting confirmation. The two sit about 82 Da apart.

02

The naming problem

Neither pen name is a chemical name.

GP-2 and GP-3 are Marogen catalog labels. The pen names GLP-2 and GLP-3 are worse, for two reasons. There is no natural hormone called GLP-3, so that name identifies nothing. GLP-2 is the opposite problem: glucagon-like peptide-2 is a real, distinct 33-residue intestinal hormone, and tirzepatide is not it.

The consequence is small but not negotiable: use tirzepatide and retatrutide in any specification, purchase order or certificate request. A document naming only GP-2, GP-3, GLP-2 or GLP-3 has not identified a molecule, and if your quality system keys on material names, those labels will not survive review.

The naming problem
LabelWhat it actually refers to
GP-2Catalog label for the tirzepatide reference standard. Not a chemical name
GLP-2, as a pen nameThe tirzepatide pen, and also a real, different intestinal hormone
GP-3Catalog label for the retatrutide reference standard. Not a chemical name
GLP-3, as a pen nameThe retatrutide pen. No hormone of that name exists
Tirzepatide, LY3298176The molecule in the GLP-2 pen. Use this name
Retatrutide, LY3437943The molecule in the GLP-3 pen. Use this name
03

The two pens as listed

Read directly from the catalog.

Both pens are listed at 20 mg total content, and neither has a published concentration or fill volume: those are supplier product facts Marogen has not put on the site. A 20 mg box strength is a quantity, not a concentration, and a graduated selector reports proportions rather than micrograms.

Both molecules are also sold as lyophilized vials in six strengths each, from 5 mg to 60 mg. For any method needing an absolute concentration the vial is the format to buy. There is no nasal spray for either.

Catalog formats covered by this guide
ListingFormSizesSKUDocumentation
GLP-2Prefilled research pen20 mgPEN-GLP2-20Not yet published
GLP-3Prefilled research pen20 mgPEN-GLP3-20Not yet published

2 catalog listings are covered here. Sizes, SKUs and documentation status are read from the catalog at build time. Blends contain more than one molecule, so only single-component listings behave as a single-analyte standard. Pricing is per account: see wholesale pricing.

04

Identification and documentation

What a certificate for either pen lot has to carry.

Identity for a peptide near 4,800 g/mol comes from multiple charge states, not from a singly charged ion. Tirzepatide shows near m/z 1204.4 for the quadruply charged ion and 963.7 for the quintuply charged; retatrutide near 1183.8 and 947.3. The molecules are about 82 Da apart, so one rounded figure cannot separate them.

For both pens the acylation is the field most often missing. A correct backbone with no fatty-diacid side chain is a different compound, several hundred daltons lighter and much more polar, and one of the likelier manufacturing failures at this size. A certificate should confirm the side chain is present and quantify unacylated material. Marogen publishes certificates by lot number at marogenbio.com/coa, with a lookup at marogenbio.com/lot. Neither pen has one today.

Identification and documentation
FieldWhat to require for either pen
Material nameTirzepatide or retatrutide, written out. Not GP-2, GP-3, GLP-2 or GLP-3
Lot numberAs printed on the pen, matching the box
IdentityObserved against calculated mass across at least two charge states
Mass basisThe formula and weight used. For retatrutide this is unsettled in public databases
Side chainThe C20 fatty-diacid conjugate present, with unacylated material quantified
Concentration in the cartridgeNot published by the catalog, and without it 20 mg is not a concentration
Fill or release dateA pen is a dated solution, so its age is part of the measurement
Purity and contentArea percent by reverse-phase HPLC with the method stated, content reported separately
05

Storage and handling in the lab

Both pens hold a surface-active lipidated peptide in solution, the hardest combination in this catalog to keep stable. The fatty-diacid chain makes the molecule adsorb to surfaces and prone to aggregation, and neither loss changes a purity figure. The points below are general laboratory practice, not a Marogen specification.

  • Record the lot number and the release or fill date on receipt, and treat the pen as a dated solution from then on.
  • Hold it at the temperature the supplier states, upright and out of light, and do not freeze a filled cartridge unless the supplier says it tolerates freezing.
  • Avoid temperature swings, which costs purity in an acylated peptide with no external sign.
  • Expect adsorption losses on any dilution into glass or plastic, and keep transfer steps to a minimum.
06

Telling the two pens apart

Outside the label, the only reliable separation is mass. The two have different backbones, but they are close enough in weight and chromatography that nothing on a quote or a box settles which one you have.

Telling the two pens apart
MaterialHow it differs and how to check
Tirzepatide, the GLP-2 pen4813.5 g/mol, GIP-based backbone, Aib at 2 and 13, C-terminal serinamide, confirmed in the FDA registry
Retatrutide, the GLP-3 pen4731.3 g/mol, glucagon-family backbone. Formula and weight unconfirmed in authoritative databases
Semaglutide (GP-1)Near 4113 g/mol with a different side chain. Listed as a vial reference standard, not as a pen
Unacylated backbone of eitherSeveral hundred daltons lighter and far more polar. A failure mode, not a grade
07

What the published literature measured

For a reference standard the useful part of each record is the structural and receptor-pharmacology work, which is what each molecule's identity was defined against.

  1. Coskun T, Sloop KW, Loghin C, et al.. Molecular Metabolism 2018; 18:3-14.

    Reported the structure, including the two Aib substitutions and the C20 fatty-diacid side chain, and measured receptor binding and cAMP responses in vitro.

  2. Willard FS, Douros JD, Gabe MB, et al.. JCI Insight 2020; 5:e140532.

    Measured receptor binding, cAMP accumulation and beta-arrestin recruitment at the GIP and GLP-1 receptors, showing the imbalance between the two.

  3. Coskun T, Urva S, Roell WC, et al.. Cell Metabolism 2022; 34:1234-1247.

    Reported the molecule's design and measured in-vitro potency at the glucagon, GIP and GLP-1 receptors, the primary source for its structure.

  4. Urva S, Coskun T, Loh MT, et al.. The Lancet 2022; 400:1869-1881.

    Reported plasma concentration-time profiles and an apparent half-life of roughly six days for the compound in a phase 1b study.

08

Wholesale availability

Both pens and both vial ranges are supplied wholesale, priced per account rather than from a public list, and one pricing request can cover pens and vials together. Ask for the concentration, fill volume and mass basis in writing against a lot number before ordering.

Apply for wholesale pricing

List the materials, sizes and units you need, or ask about the range, and say a little about the business. Pricing is set per account and confirmed on every quote, with the lot’s documentation status stated for each line.

09

Questions

What is in the GLP-2 pen?

Tirzepatide, development code LY3298176: a synthetic 39-residue lipidated peptide amide based on the human GIP sequence, with Aib at positions 2 and 13, a C20 fatty diacid at Lys20 attached through a gamma-glutamate and two glycol units, and a C-terminal serinamide. Formula C225H348N48O68, 4813.5 g/mol. The pen name GLP-2 is a supplier label and also an unrelated natural hormone.

What is in the GLP-3 pen?

Retatrutide, development code LY3437943, a synthetic lipidated peptide on a glucagon-family backbone, recorded in the FDA registry under UNII NOP2Y096GV with a 39-residue backbone. Its published formula C221H342N46O68 and weight of 4731.3 g/mol match PubChem and vendor datasheets but are not confirmed in CAS Common Chemistry. There is no hormone called GLP-3.

Why should I not use the names GP-2, GP-3, GLP-2 and GLP-3?

Because none of them identifies a molecule. GP-2 and GP-3 are catalog labels. GLP-3 refers to nothing that exists. GLP-2 refers to a real but entirely different 33-residue intestinal hormone, which makes it misleading on a tirzepatide product. Use tirzepatide and retatrutide instead.

How do I tell the two pens apart analytically?

By mass, reported properly. They sit about 82 Da apart, under two percent of the total, so one rounded figure will not settle it. Tirzepatide shows near m/z 1204.4 for the quadruply charged ion and 963.7 for the quintuply charged; retatrutide near 1183.8 and 947.3. A certificate reporting observed against calculated mass across at least two charge states, plus a sequence statement, is what you want.

Research use only. This guide describes materials supplied for in-vitro research and analytical method development. Nothing here is dosing, administration or use information, and no product on this site is offered for human or animal consumption. See the research use policy.